Community curated by people like you

Jia Guo stories

Oct 25, 2026

Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs

Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.

Oct 25, 2026·4 sources

00

Top claims

▪In the Phase III Krascendo 1 trial involving 338 patients with previously treated KRAS G12C-mutated non-small cell lung cancer, Roche's divarasib reduced the risk of death by 44% compared to approved KRAS G12C inhibitors sotorasib and adagrasib
▪The Phase III Krascendo 1 trial directly tested Roche's divarasib against Amgen Inc.'s sotorasib and Bristol-Myers Squibb Co.'s adagrasib, rather than comparing it against chemotherapy
▪Roche announced it is working with health authorities to bring divarasib to patients following the Phase III Krascendo 1 trial results

Topics

Targeted cancer therapy Cancer & Oncology Clinical trials Cancer treatment breakthroughs

Related entities

Adagrasib Madrid Sotorasib